Pfizer, Roche join $42.6M round to fund microbiome player Second Genome
Second Genome uses genomics, computational biology and phenotypic screening to identify the molecular mechanisms of the microbiome that cause disease.
Second Genome uses genomics, computational biology and phenotypic screening to identify the molecular mechanisms of the microbiome that cause disease.
Nestlé is expanding its tentacles from chocolatier into drug development – investing in companies focused on microbiota, muscle loss and Alzheimer’s disease. STAT talked with Greg Behar, CEO of the new Nestlé Health Science subsidiary of the company, on the company’s foray into the life sciences. The company’s health science subsidiary was launched five years ago, and employs […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Seres Health has raised $10 million to advance its C.difficile therapeutic to treat strains resistant to the antibiotic vancomycin, according to a company statement. It wants to combat the increasing threat hospital acquired infections pose to patients. But this innovative approach to medicine also faces some regulatory challenges. The Mayo Clinic was among the new […]